Completed PHASE1 INTERVENTIONAL 4-arm NCT01707407

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects (DDI)

Sponsor: Celgene

Conditions Healthy Pharmacology, Clinical

Interventions Carbamazepine Fluvoxamine Ketoconazole Pomalidomide

Updated 7 times since 2017 Last updated: Nov 7, 2019 Started: Sep 1, 2012 Primary completion: Nov 1, 2012 Completion: Nov 1, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01707407, this PHASE1 trial focuses on Healthy and Pharmacology, Clinical and remains completed. Sponsored by Celgene, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Dec 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States